Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.70 +0.16 (+0.65%)
Official Closing Price Updated: 7:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
US Stocks Rise Despite China's Trade Fears, Palantir Defies Gravity, Gold Rallies Further: What's Driving Markets Tuesday?
U.S. stocks advanced midday Tuesday, demonstrating resilience despite escalating geopolitical tensions and trade uncertainties between the world’s two largest economies. 
Via Benzinga
Peering Into Pfizer's Recent Short Interest
Via Benzinga
Pfizer's Retail Traders Cheer Better-Than-Expected Q4 Even As Stock Dips: ‘Another Beat And Still Crazy Cheap'
Under its restructuring program, Pfizer said it remains on track to deliver $4.5 billion in cost savings by the end of 2025. 
Via Stocktwits
RFK Jr. Clears A Key Hurdle To Head Up HHS. Why His Nomination Is A Biotech Black Box.
RFK Jr. cleared a key hurdle Tuesday after the Senate Finance Committee voted along party lines in favor of his nomination. 
Via Investor's Business Daily
Nasdaq Surges Over 1%; Pfizer Earnings Top Estimates
Via Benzinga
Robert F. Kennedy's Health Secretary Nomination Advances To Full Senate: Vaccine Stocks Drop
The U.S. Senate Finance Committee on Tuesday voted 14 to 13 in favor of advancing the nomination of Robert F. Kennedy Jr. to lead the Department of Health and Human Services. 
Via Benzinga
Pfizer Beats Q4 Revenue, EPS Estimates
Pfizer reported robust fourth-quarter 2024 earnings, exceeding expectations in both revenue and adjusted earnings. 
Via The Motley Fool
Pfizer Q4 Earnings: Revenue And EPS Beat, Seagen And COVID-19 Products Show Strength, Issues Strong FY25 Outlook
Pfizer posted Q4 revenue of $17.76 billion, up 22% YoY, with strong sales from Paxlovid, Vyndaqel, and Eliquis. The company reaffirmed its 2025 revenue outlook. 
Via Benzinga
Exposures COVID-19
Pfizer Edges Higher As Covid Sales Decline, But Still Beat Expectations
Pfizer stock rose moderately early Tuesday on the back of its quarterly beat. 
Via Investor's Business Daily
Exposures COVID-19
Pfizer (NYSE:PFE) Posts Better-Than-Expected Sales In Q4
Global pharmaceutical company Pfizer (NYSE:PFE) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 21.9% year on year to $17.76 billion. On the other hand, the... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Pfizer Reports Better Than Expected Q4 Results
Pfizer Inc. reported a strong performance for the fourth quarter of 2024, with revenues reaching $17.8 billion. 
Via Talk Markets
Topics Stocks / Equities
Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance
From Pfizer Inc.
Via Business Wire
US Stocks Likely To Open Lower As Trump's Trade War Continues To Impact The Market: 'Volatility Is The Toll We Pay To Invest,' Says Expert
U.S. stock futures were trading lower on Tuesday after Monday's decline as the new administration tariffs continued to spook the market. 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
2 Ultra-High-Yield Dividend Stocks That Are No-Brainer Buys in February
These sensational income stocks -- sporting an average yield of 6.15% -- can fatten investors' pocketbooks for a long time to come. 
Via The Motley Fool
Dow Trims Losses After Trump Delays Mexico, Canada Tariffs: Greed Index Remains In 'Fear' Zone
Via Benzinga
Topics Government Stocks
Exposures Political US Equities
Pfizer Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Via Benzinga
Earnings Scheduled For February 4, 2025
Via Benzinga
PepsiCo, Pfizer And 3 Stocks To Watch Heading Into Tuesday
US stock futures down on Tues, focus on PepsiCo, NXP Semiconductors, Pfizer earnings. UBS reports strong Q4, EA to release after market close. 
Via Benzinga
Here’s What NOT to Do the Next Time Tariffs Hit
Worried about market drops and tariff news? Discover why short-term volatility shouldn’t derail your long-term investing strategy, with lessons from Amazon and other market giants. Stay focused on... 
Via InvestorPlace
Topics World Trade
Exposures Tariff
Which S&P500 stocks are the most active on Monday?
Explore the S&P500 index on Monday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest. 
Via Chartmill
Merck Vs. Pfizer: Which Pharmaceutical Giant Will Prevail In Q4 Earnings?
Merck and Pfizer are heading into fourth quarter earnings with different technical setups, leaving investors unsure of which stock will prevail. While Merck shows short-term strength, Pfizer is... 
Via Benzinga
Activist Starboard Value Pushes Becton Dickinson To Divest Life Sciences Unit
Activist investor Starboard Value is urging Becton Dickinson to sell its life sciences division, citing potential value gains. Analysts estimate a spin-off could boost the company's worth by up to... 
Via Benzinga
Pfizer Trial For Colorectal Cancer Treatment Shows Improved Survival In Late-Stage Study
Pfizer's Braftovi combination showed significant survival benefits in a Phase 3 study for BRAF V600E-mutant metastatic colorectal cancer. 
Via Benzinga
Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
From Pfizer Inc.
Via Business Wire
Better Artificial Intelligence Stock: SoundHound AI vs. Palantir Technologies
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Current Report: Viatris Inc
Viatris Inc. is a wholly owned subsidiary of Pfizer that specializes in off-patent drugs. Share price fell about 4% in the past year from $11.88 to $11.41, as of Thursday’s market close. 
Via Talk Markets
Topics Stocks / Equities
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders
Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people. 
Via Benzinga
Topics Government
Exposures Political
Robert Kennedy Jr. Faces Senate Confirmation Hearings As Bird Flu Concerns Grow: Caroline Kennedy Says Cousin 'Predator' Unfit For Office
Robert F. Kennedy, Jr. will begin Senate confirmation hearings on Wednesday as President Donald Trump's pick to lead the Department of Health and Human Services. 
Via Benzinga
Topics Government
Exposures Political
Market Alert: PESG Releases New Report Highlighting Silexion Therapeutics as an Emerging Leader in the Multi-Billion Dollar Precision Oncology Industry
Market Alert: PESG Releases New Report Highlighting Silexion Therapeutics as an Emerging Leader in the Multi-Billion Dollar Precision Oncology Industry 
Via News Direct
The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings
The Senate will meet Wednesday to start the confirmation hearing process for Robert F. Kennedy Jr. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.